Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zura Bio Ltd

ZURA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$5.85

▲ +1.74%

Market Cap $560.60M · Vol 210.25K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$560.60M

Small Cap

Div Yield

N/A

EPS Growth

+22.41%

YoY

RSI (14)

58.97

Momentum

Beta

-0.02

vs Market

52W High

$7.40

20.95% below

52W Low

$1.88

211.17% above

Volume

210.25K

Avg 229.23K

P/B

3.80

Price-to-book

ROE

N/A

Return on equity

Free Float

80.61%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Zura Bio Ltd (ZURA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZURA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.03%

+2.99%

+31.76%

-5.65%

YTD

+11.64%

+193.97%

-13.46%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-68,650,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-46.78% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.80
P/FCF	N/A
EPS Growth	+22.41%
Outstanding Shares	95.83M

Technical Indicators

50-Day SMA	$5.17
200-Day SMA	$5.14
RSI (14)	58.97
Beta	-0.02
52-Week High	$7.40
52-Week Low	$1.88

Volume Today	210.25K
Avg Daily Volume (30D)	229.23K
Relative Volume	0.92x
Volatility (10D)	42.09
Volatility (30D)	51.82
Free Float	80.61%

Analyst Consensus

STRONG BUY

Current Price $5.85

Mean Target $18.83

52W Low$1.88 52W High$7.40

Current

Target

$1.88 $7.40

Current Analyst target

+221.94% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011FJXVZ5

ISINKYG9TY5A1016

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.39% ARGX.BR argenx SE +1.90% ARGX argenx SE +0.16% INSM Insmed Inc +0.55% 2269.HK WuXi Biologics (Cayman) Inc +2.74%

Company Profile

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.